newsfilter
← Latest News
ACCESS Newswire·

Novamind to Conduct Phase II Psilocybin Trial for Major Depressive Disorder

First patient randomization completed at Draper, Utah research site TORONTO, ON / ACCESSWIRE / March 9, 2022 / Novamind Inc. (CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicin